SpectronRx
Craig Hill is an experienced professional in the field of radiopharmaceutical development and chemistry, currently serving as Director of Radiopharmaceutical Development and Translation and Radiochemist at SpectronRx since February 2020. With a career spanning over two decades, Craig has held various roles including Advisor at Manzanita Pharmaceuticals, where technical expertise on patent applications was provided, and Medical Affairs Scientist I & II at Leidos Biomedical Research, where management of staff and budgeting in radiochemistry and clinical trials occurred. Additional experience includes teaching chemistry as Adjunct Faculty at Montgomery College and San Joaquin Delta College, and serving as a Patent Consultant for Bozicevic, Field & Francis LLP. Craig holds a PhD in Pharmaceutical Sciences from the University of Arizona and a Bachelor's degree in Biochemistry from California Polytechnic State University.
This person is not in any teams
SpectronRx
1 followers
SpectronRx is a CDMO that is FDA and EMA inspected. We are licensed to handle multiple Therapeutic and Diagnostic isotopes pharmaceutical grade including Pb-212, Lu-177, Ac-225 and I-131 for various clinical applications. Spectron operates under a quality program that has been inspected by the FDA with approved drugs FDG, NaF and Ammonia. Spectron provides labeling and contract manufacturing services as it relates to Lu-177, Ac-225, I-131, I-124, I-111, Zr-89, Copper-64 and Fluorine-18.